Repeatedly measuring the level of Advanced Glycation Endproducts (AGEs) in the acute phase of a myocardial infarction.
- Conditions
- ST-segment elevation myocardial infarction (STEMI), Acute Coronary Syndrome (ACS), myocardinfarct
- Registration Number
- NL-OMON28558
- Lead Sponsor
- Erasmus Medical Center, RotterdamProf. Eric Boersma, MSc, PhD, FESC, Professor of clinical epidemiology of cardiovascular diseases.
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
The following inclusion criteria will be applied (all criteria should apply):
1. Men and women, aged from 18 to 70 years, capable of understanding the study content of and willing to provide written informed consent at admission to the hospital;
Exclusion Criteria
Patients with at least one of the following characteristics will be excluded:
1. Myocardial ischemia precipitated by a condition other than atherosclerotic coronary artery disease;
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoints are serial measurements of a) skin AF by the AGE reader® and b) value of AGEs as measured in serum. Furthermore, cardiac enzymes levels will be assessed repeatedly to determine the area under the curve for estimation of the infarct size.
- Secondary Outcome Measures
Name Time Method